Synthesis AI
United States
- San Francisco, California
- 28/04/2022
- Series A
- $17,000,000
Pioneering synthetic data technology to build more capable and ethical AI.
- Industry Software Development
- Website https://synthesis.ai/
- LinkedIn https://www.linkedin.com/company/synthesis-ai/
Related People
Yashar BehzadiFounder
United States -
San Francisco Bay Area
Proven executive, experienced technologist, and meticulous product lead with a history of delivering first-in-class products to market.
Specialties:
- Early venture strategy and financing
- Developing novel technologies
- New product introduction and market development across industries
- Building strong teams
- Leading complex and multifaceted product development programs
- Structuring and leading strategic partnerships with large companies
Highlights:
- Launched world's first digital medicines product system (ingestible sensor+pharmaceuticals+wearables+apps)
- Developed first AI-based diagnostic test for broad-spectrum mental illness based on a panel of biomarkers
- 8 years of experience building best-in-class wearables (FDA-approved, CE-marked)
- Pioneered synthetic data technologies for building more capable AI models
- 30+ patents across hardware & software (https://patents.justia.com/inventor/yashar-behzadi)
Pinnacle Medicines | $89,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
Mirage | $75,000,000 | (Mar 27, 2026)
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)
Payy | $6,000,000 | (Mar 27, 2026)
Conntour | $7,000,000 | (Mar 27, 2026)
KilgourMD | Undisclosed Amount | (Mar 27, 2026)
Terrestrial | $50,000,000 | (Mar 27, 2026)
Krane | $9,000,000 | (Mar 26, 2026)
Zalos (YC F25) | $3,600,000 | (Mar 26, 2026)